Market Overview

UPDATE: Piper Jaffray Downgrades LabCorp of America to Neutral on Softening Volume Outlook

Share:
Related LH
Why Laboratory Corp Is Underappreciated By The Street
Canaccord Genuity Upgrades Laboratory of America To Buy
MedTech M&As Continue Regardless of Tax Scenarios - Industry Outlook (Zacks)

Piper Jaffray reduced its rating on LabCorp of America (NYSE: LH) from Overweight to Neutral and lowered its price target from $100 to $96.

Piper Jaffray commented, "We are downgrading LH to Neutral and lowering our PT to $96 (13x FY13E EPS) as we believe weak employment growth could lead to slower than expected organic volume growth. Additionally, the recent run in the stock, coupled with potentially weak volume growth and a lack of near-term catalysts, could lead to a pullback or at least keep the stock range-bound over the next several months. While LH could report upside to Q2 EPS on Thursday, likely driven by share repurchases and modest pricing growth, we do not expect a favorable stock reaction."

LabCorp of America closed at $94.62 on Monday.

Latest Ratings for LH

DateFirmActionFromTo
Mar 2015Maxim GroupMaintainsBuy
Mar 2015Canaccord GenuityUpgradesHoldBuy
Mar 2015BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for LH
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (LH)

Around the Web, We're Loving...